Marked efficacy of combined three-drug therapy (Sodium Valproate, Topiramate and Stiripentol) in a patient with Dravet syndrome.

Abstract

WHAT IS KNOWN AND OBJECTIVE:

Dravet syndrome (DS) is an intractable epilepsy syndrome. The three-drug combination therapy of sodium valproate (VPA), clobazam (CLB) and stiripentol (STP) is recommended worldwide.

CASE SUMMARY:

We present a case of DS, in which treatment with CLB could not be continued because of the appearance of adverse reactions to it. Replacement with topiramate (TPM) proved to be markedly effective.

WHAT IS NEW AND CONCLUSION:

It is suggested that combination therapy with VPA, TPM and STP is for DS epilepsy.

• Authors: M Morimoto, S Shimakawa, T Hashimoto, T Kitaoka, S Kyotani
• Journal: Journal of clinical pharmacy and therapeutics (J Clin Pharm Ther) Vol. 43 Issue 4 Pg. 571-573 (Aug 2018) ISSN: 1365-2710 [Electronic] England
• PMID: 29265387 (Publication Type: Case Reports)
• Copyright: © 2017 John Wiley & Sons Ltd.

Chemical References

• Anticonvulsants
• Dioxolanes
• Topiramate
• Fructose
• Valproic Acid
• stiripentol

Topics

• Anticonvulsants (adverse effects, therapeutic use)
• Child, Preschool
• Dioxolanes (adverse effects, therapeutic use)
• Drug Therapy, Combination (methods)
• Epilepsies, Myoclonic (drug therapy)
• Epilepsy (drug therapy)
• Female
• Fructose (adverse effects, analogs & derivatives, therapeutic use)
• Humans
• Topiramate
• Valproic Acid (adverse effects, therapeutic use)